Evidence map›Paper›PMID 29657832›Full record

ArticleRMD open2018

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis.

Lieke Tweehuysen, Nathan den Broeder, Noortje van Herwaarden, Leo A B Joosten, Peter L van Lent, Thomas Vogl, Frank H J van den Hoogen, Rogier M Thurlings, Alfons A den Broeder

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Virtual Probing on the Influence of CaCell biochemistry and biophysics · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. S100 proteins in rheumatic diseases.Nature reviews. Rheumatology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Lieke TweehuysenDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Nathan den BroederDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Noortje van HerwaardenDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Leo A B JoostenDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Peter L van LentDepartment of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Thomas VoglDepartment of Immunology, University of Münster, Münster, Germany.
Frank H J van den HoogenDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Rogier M ThurlingsDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Alfons A den BroederDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Radboud University Nijmegen · NLSint Maartenskliniek · NLUniversity of Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCalprotectin (S100A8/A9) has been correlated with disease activity in rheumatoid arthritis (RA). The aim of this study was to investigate the predictive value of serum calprotectin for clinical response after starting and tapering anti-tumour necrosis factor treatment in RA.

methodsSerum samples and clinical outcomes were derived from two longitudinal RA studies.At baseline (starting or tapering of adalimumab or etanercept), calprotectin levels were determined by ELISA. In the Biologic Individual Optimised Treatment Outcome Prediction (BIO-TOP) study, treatment effect was assessed after 6 months using the European League Against Rheumatism (EULAR) response criteria. In the Dose Reduction Strategies of Subcutaneous TNF Inhibitors (DRESS) study, patients were classified at 18 months as being successfully dose reduced, discontinued or not able to reduce the dose. Area under the receiver operating characteristic curves (AUC) were generated to evaluate the predictive value of calprotectin and logistic prediction models were created to assess its added value.

resultsIn the BIO-TOP study, calprotectin levels were higher in responders (n=50: 985 ng/mL (p25-p75: 558-1417)) compared with non-responders (n=75: 645 ng/mL (p25-p75: 415-973), p=0.04).AUC for predicting EULAR good response was 0.61 (95% CI 0.50 to 0.71). The prediction model with calprotectin (AUC 0.77, 95% CI 0.68 to 0.85) performed similarly to the baseline model (AUC 0.74, 95% CI 0.65 to 0.82, p=0.29). In the DRESS study, calprotectin levels were similar between the three groups (n=47; n=19; n=36) and calprotectin was not predictive for clinical response after tapering.

conclusionsSerum calprotectin has some predictive value for clinical response after starting anti-TNF treatment, although it has no added value to other clinical factors. In patients with low disease activity, serum calprotectin is not predictive for clinical response after tapering anti-TNF treatment. TRIAL REGISTRATION NUMBER: NTR4647 (BIO-TOP study) and NTR3216 (DRESS study); Pre-results.

Indexed as

biologic agentsbiomarkerscalprotectinprediction of responserheumatoid arthritistapering

Identifiers

PMID29657832
PMCPMC5892754
OpenAlexW2797251235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.